CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

NCT06041776 · Phase 3 · Recruiting

PHASEPhase 3

STATUSRecruiting

ENROLLMENT570

EST. COMPLETION2028-04-30

Conditions

Non-Small Cell Lung CancerEGFR Sensitive MutationAdjuvant Therapy

Interventions

Befotertinib + Icotinib placeboIcotinib + Befotertinib placebo

Study details

SPONSORBetta Pharmaceuticals Co., Ltd.

START DATE2023-03-28

Related company profiles

Betta Pharmaceuticals

300558.SZ

Primary source

ClinicalTrials.gov record NCT06041776 ↗

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier: NCT06041776
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record